#Plans stage monitor series#

In the last 2 years, been treated with anti-CD20 agents or similar therapeutic agents: examples include rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumomab, tositumomab.

Prior AIDS defining illness or prior CD4 count ≤ 200/mm3 or prior CD4 fraction ≤ 15% or any detectable plasma viral load since January 2021 or HIV infection and ≥ 65 years old or perinatally acquired HIV infection.Īre on active treatment with the following categories of immunosuppressive therapies:

Have a diagnosis of CLL/SLL, myeloma/plasmacytoma, or low grade lymphoma.

Are planned for radiation, are having or will have had radiation in the last 3 months.

Will have, are having, or in the last 6 months have received anti-cancer systemic therapy for solid tumours (including but not limited to cytotoxic chemotherapy molecular targeted therapy immunotherapy monoclonal antibodies bone modifying agents used in the setting of metastatic disease high dose steroids e.g equivalent to > 20mg/day for more than 1 month but excluding patients only receiving hormonal or bone modifying therapy in the adjuvant setting).

Will have, are having, or in the last 24 months have had a bone marrow, stem cell transplant or CAR-T or who are still taking immunosuppressive drugs.

Will have, are having, or in the last 12 months have received systemic treatment for a haematological malignancy, or in the last 24 months have received anti-CD20 or other B-cell depleting therapies for a haematologic malignancy.

Will have, are having, or are on active treatment for solid tumour or hematologic malignancies (like myeloma or leukemia): May include a heart, lung, liver, kidney, pancreas or islet cells, bowel or combination organ transplant Have had a solid-organ transplant and are taking immunosuppressive therapy: Moderately to severely immunocompromised dose 3 criteria

People who are moderately to severely immunocompromised and meet the criteria need a third dose of vaccine to complete their initial series.

#Plans stage monitor series#

People with moderately to severely compromised immune systems will generally have lower antibody responses from two COVID-19 vaccine doses. Studies show that giving a third dose to complete the initial vaccine series can help these individuals create antibodies to protect them from COVID-19.